12,625 research outputs found

    GERIATRĂŤA: Algunos aspectos de la edad senil

    Get PDF

    Effects of P-wave Annihilation on the Angular Power Spectrum of Extragalactic Gamma-rays from Dark Matter Annihilation

    Get PDF
    We present a formalism for estimating the angular power spectrum of extragalactic gamma-rays produced by dark matter annihilating with any general velocity-dependent cross section. The relevant density and velocity distribution of dark matter is modeled as an ensemble of smooth, universal, rigid, disjoint, spherical halos with distribution and universal properties constrained by simulation data. We apply this formalism to theories of dark matter with p-wave annihilation, for which the relative-velocity-weighted annihilation cross section is \sigma v=a+bv^2. We determine that this significantly increases the gamma-ray power if b/a >> 10^6. The effect of p-wave annihilation on the angular power spectrum is very similar for the sample of particle physics models we explored, suggesting that the important effect for a given b/a is largely determined by the cosmic dark matter distribution. If the dark matter relic from strong p-wave theories is thermally produced, the intensities of annihilation gamma-rays are strongly p-wave suppressed, making them difficult to observe. If an angular power spectrum consistent with a strong p-wave were to be observed, it would likely indicate non-thermal production of dark matter in the early Universe.Comment: 20 pages, 3 figure

    Opposite Arrows of Time Can Reconcile Relativity and Nonlocality

    Full text link
    We present a quantum model for the motion of N point particles, implying nonlocal (i.e., superluminal) influences of external fields on the trajectories, that is nonetheless fully relativistic. In contrast to other models that have been proposed, this one involves no additional space-time structure as would be provided by a (possibly dynamical) foliation of space-time. This is achieved through the interplay of opposite microcausal and macrocausal (i.e., thermodynamic) arrows of time.Comment: 12 pages, 4 figures; v5: section headlines adde

    Monensin causes dose dependent inhibition of Mycobacterium avium subspecies paratuberculosis in radiometric culture

    Get PDF
    <p>Abstract</p> <p>Background</p> <p><it>Mycobacterium avium </it>subspecies <it>paratuberculosis </it>(MAP) causes a chronic wasting diarrheal disease in ruminants called Johne's disease, that is evocative of human inflammatory bowel disease (IBD). Agents used to treat IBD, called "anti-inflammatories", immuno-modulators" and "immuno-suppressants" inhibit MAP growth in culture. We concluded that, unknowingly, the medical profession has been treating MAP since sulfasalazine's introduction in 1942. Monensin, called a "Growth Enhancer" in cattle, ameliorates Johne's disease without a documented mechanism of action. We hypothesized that Monensin would inhibit MAP in culture.</p> <p>Methods</p> <p>Using the radiometric <sup>14</sup>CO<sub>2 </sub>Bactec<sup>® </sup>system, that expresses mycobacterial growth in arbitrary growth index (GI) units, we studied the effect of Monensin on the growth kinetic of MAP isolated from humans with IBD ("Dominic", "Ben" & UCF-4) and cattle with Johne's disease (303 & ATCC 19698.) Results are expressed as percent inhibition of cumulative GI (%–ΔcGI).</p> <p>Results</p> <p>The positive control Clofazimine inhibits every strain tested. The negative controls Cycloheximide & Phthalimide, have no inhibition on any MAP strain. Monensin has dose dependent inhibition on every MAP strain tested. The most susceptible human isolate was UCF-4 (73% – ΔcGI at 1 μg/ml) and bovine isolate was 303 (73% – ΔcGI at 4 μg/ml.) Monensin additionally inhibits <it>M. avium </it>ATCC 25291 (87% – ΔcGI at 64 μg/ml) & BCG (92% – ΔcGI at 16 μg/ml).</p> <p>Discussion</p> <p>We show that in radiometric culture the "Growth Enhancer" Monensin causes dose dependent inhibition of mycobacteria including MAP. We posit that the "Growth Enhancer" effect of Monensin may, at least in part, be due to inhibition of MAP in clinical or sub-clinical Johne's disease.</p
    • …
    corecore